The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: A retrospective chart review study

Abstract Retrospective chart review of CBD use in patients with LGS and DS in a UK EAP. CBD retention for patients not lost to follow up was 14/19 (74 %) at 12 months. AESIs were reported in 70 % and 53 % of patients at 6 and 12 months, respectively. Results on CBD effectiveness and safety are consistent with previous studies. Article type: Research Article Keywords: Lennox-Gastaut syndrome, Dravet syndrome, Cannabidiol, Seizure, Early Access Program, Clinical practice Authors: Christin Eltze,